Catherine M. Kelly

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley et al. · Journal of Clinical Oncology · 2018 · 519 citations · Full text

Medicine, Oncology, Pharmacology +17

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

Catherine M. Kelly, David N. Juurlink, Tara Gomes et al. · BMJ · 2010 · 461 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Fátima Cardoso, John M.S. Bartlett, Leen Slaets et al. · Annals of Oncology · 2017 · 399 citations · Full text

Medicine, Oncology, Surgery +15

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Luca Gianni, Chiun‐Sheng Huang, Daniel Egle et al. · Annals of Oncology · 2022 · 386 citations · Full text

Medicine, Oncology, Pharmacology +15

Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆

Filippo Montemurro, Suzette Delaloge, Carlos H. Barrios et al. · Annals of Oncology · 2020 · 342 citations · Full text

Medicine, Oncology, Pharmacology +17